Skip to content

Psilocybin for depression: all studies

Page 43 of 51: studies 421 to 430 of 509, newest first. Back to the psilocybin for depression overview

Research

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

CNS Drugs November 17, 2021 Susan Ling, Felicia Ceban, Leanna M.W. Lui et al. 123 citations

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and...

DOI: 10.1007/s40263-021-00877-y (opens in new tab) Psilocybin Serotonergic Serotonin Neurochemical +6

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.

Translational Psychiatry November 8, 2021 Manoj K. Doss, Michal Považan, Monica D Rosenberg et al. 343 citations

Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have proposed neuropsychoplastogenic effects as mechanisms underlying the enduring therapeutic effects of psilocybin. In an open-label study of 24 patients with major depressive disorder, we tested the enduring effects of psilocybin...

DOI: 10.1038/s41398-021-01706-y (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Neuroplasticity Psilocybin therapy Psychedelic treatment +20

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Pharmaceuticals September 28, 2021 René Zeiss, Maximilian Gahr, Heiko Graf 17 citations

There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we...

DOI: 10.3390/ph14100985 (opens in new tab) Psilocybin Major depressive disorder Antidepressant Hallucinogen +2

Psilocybin: Next to treat depression, OCD and nicotine addiction

Alcoholism & Drug Abuse Weekly September 24, 2021 Alison Knopf

First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.

DOI: 10.1002/adaw.33204 (opens in new tab) Psilocybin Cannabis Nicotine addiction Advertising

Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies

Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...

DOI: 10.1016/j.jadr.2021.100240 (opens in new tab) Full text (opens in new tab) Psilocybin Depression economics Bipolar disorder Psychotherapist +3

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

DOI: 10.1016/j.jad.2021.09.041 (opens in new tab)

Is MDD the right target for early-stage psychedelic-assisted therapy trials?

Journal of Psychedelic Studies September 15, 2021 Benjamin R. Lewis, Kevin Byrne 1 citation

Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major Depressive Disorder (MDD) should raise concerns for this illness category as a target of early psychedelic research given a goal of FDA approval. There are three reasons why MDD is the wrong...

DOI: 10.1556/2054.2021.00180 (opens in new tab) Full text (opens in new tab) Major depressive disorder Psilocybin Anxiety Psychological intervention +9

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis

Journal of Psychopharmacology September 14, 2021 Robert F. Leger, Ellen M. Unterwald 54 citations

Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and enduring positive effect on mood. However, marked heterogeneity between methodological designs in this emerging field remains a significant concern. Aims: To determine how differences in the type of psychedelic agent used and...

DOI: 10.1177/02698811211044688 (opens in new tab) Psilocybin Anxiety Lysergic acid diethylamide Serotonin +9

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Journal of Neurochemistry September 14, 2021 Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr et al. 78 citations

Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long‐term after only a single treatment. Indeed, the Food and Drug...

DOI: 10.1111/jnc.15509 (opens in new tab) Psilocybin Major depressive disorder Hallucinogen Neurology +1